Evidence map›Paper›PMID 36313093›Full record

ArticleFrontiers in nutrition2022

Molecular docking and antihypertensive effects of a novel angiotensin-I converting enzyme inhibitory peptide from yak bone.

Xinchang Gao, Fan Bu, Dalong Yi, Huaigao Liu, Zhiying Hou, Chaoying Zhang, Chang Wang, Jin-Ming Lin, Yali Dang, Yufen Zhao

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinchang GaoDepartment of Chemistry, Tsinghua University, Beijing, China.
Fan BuCollege of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, China.
Dalong YiAnhui Guotai Biotechnology Co., Ltd., Xuancheng, China.
Huaigao LiuAnhui Guotai Biotechnology Co., Ltd., Xuancheng, China.
Zhiying HouInstitute of Drug Discovery Technology, Ningbo University, Ningbo, China.
Chaoying ZhangDepartment of Chemistry, Tsinghua University, Beijing, China.
Chang WangDepartment of Chemistry, Tsinghua University, Beijing, China.
Jin-Ming LinDepartment of Chemistry, Tsinghua University, Beijing, China.
Yali DangCollege of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, China.
Yufen ZhaoDepartment of Chemistry, Tsinghua University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel angiotensin-converting enzyme (ACE) inhibitory peptide ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPVSAVRA) was purified and identified from yak bone by Electrospray Ionization-Time of Flight-Mass Spectrometry (ESI-TOF-MS). Results

Indexed as

ACE inhibitory peptideantihypertensive effectsdigestionmolecular dockingyak bone

Identifiers

PMID36313093
PMCPMC9605770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.